Dublin, Ireland, 29 Mar 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a […]
Afimmune looking to initiate Pivotal study in 2023 Dublin, Ireland, 4 January 2023: Afimmune, a privately held, clinical stage biopharmaceutical company developing novel therapeutics for the […]
Dublin, Ireland, 19 September 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted orphan drug designation […]
Dublin, Ireland, 19 July 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) in the United States […]
Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Dublin, Ireland, 26th August 2021 – Afimmune, a clinical stage drug discovery […]
